ArticleCancer letters2018
S100B suppression alters polarization of infiltrating myeloid-derived cells in gliomas and inhibits tumor growth.
Open access · hybridAbstract read
In one paragraph
Article in Cancer letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Repurposing neurological drugs for brain cancer therapeutics: A systematic approach to identify charged molecules for affinity-based local drug delivery systems.International journal of pharmaceutics · 2025Pooled it
- Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020Pooled it
- Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment.International journal of molecular sciences · 2026Review
- Article
- S100B drives glioblastoma invasion and migration through TGF‑β2‑mediated epithelial‑mesenchymal transition.Oncology reports · 2026Article
- Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment.Journal of advanced research · 2025Review
- Roles of the Receptor for Advanced Glycation End Products and Its Ligands in the Pathogenesis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.Current issues in molecular biology · 2024Review
- RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression.Neuro-oncology · 2023Article
- Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma.Cell death & disease · 2023Review
- The Regulation of Microglial Cell Polarization in the Tumor Microenvironment: A New Potential Strategy for Auxiliary Treatment of Glioma-A Review.Cellular and molecular neurobiology · 2023Review
- Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas.Current neuropharmacology · 2023Review
- RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.International journal of molecular sciences · 2022Review
- Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers.Biomolecules · 2022Review
- Alarm Signal S100-Related Signature Is Correlated with Tumor Microenvironment and Predicts Prognosis in Glioma.Disease markers · 2022Article
- Signal Pathways Involved in the Interaction Between Tumor-Associated Macrophages/TAMs and Glioblastoma Cells.Frontiers in oncology · 2022Review
- The Role of the S100 Protein Family in Glioma.Journal of Cancer · 2022Review
- Circ_MUC16 attenuates the effects of Propofol to promote the aggressive behaviors of ovarian cancer by mediating the miR-1182/S100B signaling pathway.BMC anesthesiology · 2021Article
- Review
- Emerging role of S100B protein implication in Parkinson's disease pathogenesis.Cellular and molecular life sciences : CMLS · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Hang GaoDepartment of Bone and Joint Surgery, No.1 Hospital of Jilin University, Changchun, Jilin Province, PR China. Electronic address: 13500805575@163.com.
Ian Y ZhangDivision of Neurosurgery, City of Hope Beckman Research Institute, USA. Electronic address: izhang@coh.org.
Leying ZhangDivision of Neurosurgery, City of Hope Beckman Research Institute, USA. Electronic address: lzhang@coh.org.
Yanyan SongDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin Province, PR China. Electronic address: 328400695@qq.com.
Shunan LiuDepartment of Pharmacology, The Pharmacy School of Jilin University, Changchun, Jilin Province, PR China. Electronic address: liusn14@mails.jlu.edu.cn.
Hui RenDepartment of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, PR China. Electronic address: hren@jlu.edu.cn.
Huili LiuDivision of Neurosurgery, City of Hope Beckman Research Institute, USA. Electronic address: lulu923@126.com.
Hui ZhouCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang Province, PR China. Electronic address: zhouhui@zju.edu.cn.
Yanping SuCollege of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, PR China. Electronic address: Solar_a@sina.com.cn.
Yihang YangDepartment of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, PR China. Electronic address: yangyihangyy@163.com.
Behnam BadieDepartment of Cancer Immunotherapeutics & Tumor Immunology, City of Hope Beckman Research Institute, Duarte, CA 91010, USA. Electronic address: bbadie@coh.org.
City Of Hope National Medical Center · USJilin University · CNSecond Affiliated Hospital of Jilin University · CNBeckman Research InstituteCity of Hope · USFujian Medical University · CNShandong University · CNZhejiang University · CN
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MRole of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain TumorsR01CA155769 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BADIE, BEHNAM · 2011 to 2021
$3.8MDynamic Magnetic Targeting of Activated Brain Macrophages for Glioma TherapyR21NS081594 · NINDS · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BADIE, BEHNAM, BERLIN, JACOB M · 2013 to 2014
$465kNovel Cell Delivery Method for Brain Tumor TherapyR21CA189223 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BADIE, BEHNAM · 2014 to 2015
$414kNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA155769NCI NIH HHS R21 CA189223NINDS NIH HHS R21 NS081594
Abstract
S100B, a member of the multigene family of Ca
Indexed as
AnimalsBrain NeoplasmsCell Line, TumorDuloxetine HydrochlorideGliomaHumansKaplan-Meier EstimateMacrophage ActivationMacrophagesMiceMyeloid CellsS100 Calcium Binding Protein beta SubunitSerotonin and Noradrenaline Reuptake InhibitorsTumor BurdenTumor MicroenvironmentDuloxetine HydrochlorideS100 Calcium Binding Protein beta SubunitSerotonin and Noradrenaline Reuptake InhibitorsBrain tumorDuloxetineGlioblastomaMicrogliaRAGESerotonin-norepinephrine reuptake inhibitorTumor-associated macrophages
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.